New Anti-Anginal Drugs: Ranolazine

Title:New Anti-Anginal Drugs: Ranolazine

Volume: 13 Issue: 1

Author(s): Chiara Cavallino, Manuela Facchini, Alessia Veia, Sara Bacchni, Andrea Rognoni, Francesco Rametta, Alessandro Lupi and Angelo S. Bongo

Affiliation:

Keywords: Calcium antagonist, coronary artery disease, ranolazine, stable angina, β-blockers, nitrogen.

Abstract: Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.

Cite this article as:

Cavallino Chiara, Facchini Manuela, Veia Alessia, Bacchni Sara, Rognoni Andrea, Rametta Francesco, Lupi Alessandro and Bongo S. Angelo, New Anti-Anginal Drugs: Ranolazine, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (1) . https://dx.doi.org/10.2174/1871525713666141219112841